These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 32981290)

  • 1. Hepatic Hippo signaling inhibits development of hepatocellular carcinoma.
    Liu Y; Wang X; Yang Y
    Clin Mol Hepatol; 2020 Oct; 26(4):742-750. PubMed ID: 32981290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic Hippo signaling inhibits protumoural microenvironment to suppress hepatocellular carcinoma.
    Kim W; Khan SK; Liu Y; Xu R; Park O; He Y; Cha B; Gao B; Yang Y
    Gut; 2018 Sep; 67(9):1692-1703. PubMed ID: 28866620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the transcriptional coactivators YAP/TAZ in liver cancer.
    Zhang S; Zhou D
    Curr Opin Cell Biol; 2019 Dec; 61():64-71. PubMed ID: 31387016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hippo signaling pathway in companion animal diseases, an under investigated signaling cascade.
    Budel SJ; Penning MM; Penning LC
    Vet Q; 2021 Dec; 41(1):172-180. PubMed ID: 33945400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complex roles of Hippo-YAP/TAZ signaling in hepatocellular carcinoma.
    Shi H; Zou Y; Zhong W; Li Z; Wang X; Yin Y; Li D; Liu Y; Li M
    J Cancer Res Clin Oncol; 2023 Nov; 149(16):15311-15322. PubMed ID: 37608027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TAZ is indispensable for c-MYC-induced hepatocarcinogenesis.
    Wang H; Zhang S; Zhang Y; Jia J; Wang J; Liu X; Zhang J; Song X; Ribback S; Cigliano A; Evert M; Liang B; Wu H; Calvisi DF; Zeng Y; Chen X
    J Hepatol; 2022 Jan; 76(1):123-134. PubMed ID: 34464659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway.
    Jang JW; Kim MK; Bae SC
    Small GTPases; 2020 Jul; 11(4):280-288. PubMed ID: 29457552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiological and pathological roles of the Hippo-YAP/TAZ signaling pathway in liver formation, homeostasis, and tumorigenesis.
    Nishina H
    Cancer Sci; 2022 Jun; 113(6):1900-1908. PubMed ID: 35349740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evodiamine inhibits proliferation and promotes apoptosis of hepatocellular carcinoma cells via the Hippo-Yes-Associated Protein signaling pathway.
    Zhao S; Xu K; Jiang R; Li DY; Guo XX; Zhou P; Tang JF; Li LS; Zeng D; Hu L; Ran JH; Li J; Chen DL
    Life Sci; 2020 Jun; 251():117424. PubMed ID: 32057900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcatheter arterial chemoembolization combined with Hippo/YAP inhibition significantly improve the survival of rats with transplanted hepatocellular carcinoma.
    Quan Y; Li Z; Zhu K; Liang J
    Lipids Health Dis; 2021 Jul; 20(1):74. PubMed ID: 34304741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. USP1 modulates hepatocellular carcinoma progression via the Hippo/TAZ axis.
    Liu D; Li Q; Zang Y; Li X; Li Z; Zhang P; Feng C; Yang P; Cui J; Sun Y; Wei T; Su P; Zhao X; Yang H; Ding Y
    Cell Death Dis; 2023 Apr; 14(4):264. PubMed ID: 37041150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.
    Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T
    Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. YAP/TAZ for cancer therapy: opportunities and challenges (review).
    Guo L; Teng L
    Int J Oncol; 2015 Apr; 46(4):1444-52. PubMed ID: 25652178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interacting network of Hippo, Wnt/β-catenin and Notch signaling represses liver tumor formation.
    Kim W; Khan SK; Yang Y
    BMB Rep; 2017 Jan; 50(1):1-2. PubMed ID: 27881216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TAZ target gene ITGAV regulates invasion and feeds back positively on YAP and TAZ in liver cancer cells.
    Weiler SME; Lutz T; Bissinger M; Sticht C; Knaub M; Gretz N; Schirmacher P; Breuhahn K
    Cancer Lett; 2020 Mar; 473():164-175. PubMed ID: 31904487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNAs Regulating Hippo-YAP Signaling in Liver Cancer.
    Lee NH; Kim SJ; Hyun J
    Biomedicines; 2021 Mar; 9(4):. PubMed ID: 33808155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Research progress in role of Hippo signaling pathway in diagnosis and treatment for hepatocellular carcinoma.
    Ma J; Huang X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Jun; 46(6):637-643. PubMed ID: 34275933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Research advances in the role of the Hippo-YAP/TAZ signaling pathway in primary liver cancer].
    Guo LW; Shao GL
    Zhonghua Gan Zang Bing Za Zhi; 2017 Nov; 25(11):878-880. PubMed ID: 29325286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct and Overlapping Roles of Hippo Effectors YAP and TAZ During Human and Mouse Hepatocarcinogenesis.
    Wang H; Wang J; Zhang S; Jia J; Liu X; Zhang J; Wang P; Song X; Che L; Liu K; Ribback S; Cigliano A; Evert M; Wu H; Calvisi DF; Zeng Y; Chen X
    Cell Mol Gastroenterol Hepatol; 2021; 11(4):1095-1117. PubMed ID: 33232824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential requirement of Hippo cascade during CTNNB1 or AXIN1 mutation-driven hepatocarcinogenesis.
    Liang B; Wang H; Qiao Y; Wang X; Qian M; Song X; Zhou Y; Zhang Y; Shang R; Che L; Chen Y; Huang Z; Wu H; Monga SP; Zeng Y; Calvisi DF; Chen X; Chen X
    Hepatology; 2023 Jun; 77(6):1929-1942. PubMed ID: 35921500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.